Current and forthcoming studies of vaccines to prevent HIV infection have created a new optimism that the long and challenging road to the development of such a vaccine has begun to take some promising turns. Updates on the search for preventive vaccines, presented at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa, included information on advances in the development of novel vaccines, and in the field of antibody mediated prevention (AMP).
19 July 2016 | AIDS 2016
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
15 July 2016 | Treatment Action Group
In the study, researchers worked with a species of Old World monkeys, rhesus macaques to reproduce the trial results of RV144, the only HIV vaccine that has been tested and shown to reduce the rate of HIV acquisition in a phase III clinical trial.
08 July 2016 | Eurekalert Inf Dis
What’s on the horizon of HIV prevention? Here are five clinical trials to pay attention to, if you’re interested in what the next big breakthrough in the HIV prevention field may be.
30 June 2016 | BETA blog
A phase II clinical trial conducted in South Africa has confirmed that the therapeutic Tat vaccine against HIV/AIDS can effectively improve the response to antiretroviral drugs in people living with HIV. The results are published today in the peer-review open access Journal Retrovirology.
13 June 2016 | Istituto Superiore di Sanità press release
The first men in England have started receiving the vaccination as part of a pilot to stamp out cancers and genital disease. The scheme went live in two clinics this week and will eventually see 40,000 men vaccinated to protect them against penile, anal and other cancers. The project is specifically targeted at men who have sex with men, but ministers are exploring the possibility of rolling out the HPV vaccine to all boys.
08 June 2016 | Evening Standard
Researchers with the International Aids Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI) have built tiny particles that resemble HIV on their outside and used them to provoke an immune response in animals. Their work, which was published today in the journal Cell Reports, could advance the design of an effective AIDS vaccine.
23 May 2016 | IAVI
The US National Institute of Allergy and Infectious Diseases (NIAID) and its partners have decided to advance an experimental HIV vaccine regimen into a large clinical trial, the first for seven years. This new study, called HVTN 702, is designed to determine whether the vaccine is safe, tolerable and effective at preventing HIV infection among South African adults. The trial will begin in November 2016, pending regulatory approval. It will recruit 5400 HIV-uninfected men and women aged 18 to 35 years who are at risk for HIV infection.
18 May 2016 | National Institute of Allergy and Infectious Diseases
he new target is part of the HIV envelope called the 'fusion peptide', and its structure is simpler than the sites that past HIV vaccine attempts have focussed on. This offers hope that, this time, we might have more luck getting the body to recognise and shut down the virus before it's too late.
16 May 2016 | ScienceAlert
The research showed that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens (molecules capable of inducing an immune response).
13 April 2016 | EASL press release